Skip to content
Review Open access

Rimegepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Migraine is a leading cause of global disability, often requiring effective preventive strategies to reduce disease burden and improve patient quality of life. Rimegepant is an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. Although its efficacy in the acute treatment of migraine is well established, its role in prevention remains less comprehensively synthesized. Objective: We aimed to perform a systematic review and meta-analysis to evaluate the efficacy and safety of rimegepant for migraine prophylaxis. Methods: Embase, PubMed, and Cochrane Library were searched for randomized controlled trials (RCTs) comparing rimegepant with placebo for preventive treatment of migraine in adults. We computed mean difference (MD) for continuous outcomes and risk ratio (RR) for binary endpoints, with 95% confidence intervals (CIs). Heterogeneity was assessed using I² statistics. Statistical analyses were performed using Review Manager Web version 9.15.2. Results: We included 3 RCTs, encompassing 1721 patients, of whom 50.26% received rimegepant therapy with a follow-up of 16 weeks. Rimegepant was associated with a reduction in monthly migraine days (MMD) from the observational period through the double-blind treatment (DBT) phase (MD -1.29; 95% CI -1.80 to -0.79; p < 0.00001; I² = 64%). This reduction was observed in the first month of DBT phase (MD -1.59; 95% CI -2.00 to -1.19; p < 0.00001; I² = 37%) and persisted through the last month of DBT phase (MD -1.11; 95% CI -1.46 to -0.75; p < 0.00001; I² = 0%). In terms of safety, there were no significant differences between rimegepant and placebo for nasopharyngitis (RR 0.82; 95% CI 0.54 to 1.23; p = 0.33; I² = 34%), upper respiratory tract infection (RR 0.63; 95% CI 0.33 to 1.19; p = 0.15; I² = 0%), and urinary tract infection (RR 0.94; 95% CI 0.48 to 1.85; p = 0.85; I² = 0%). A borderline increased risk of nausea was observed with rimegepant (RR 2.01; 95% CI 1.01 to 4.00; p = 0.05; I² = 0%). Conclusion: In this meta-analysis of RCTs, rimegepant was associated with reduced MMD compared with placebo and an overall favorable safety profile, although a borderline increased risk of nausea was observed.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.